

June 21, 2022 01:16 PM GMT

Public Policy Brief | North America

What Will DC Do? FAQs on Inflation Fighting

Headlines have been swirling about potential policies being pursued in the name of fighting inflation (i.e., tariff cuts, a windfall profits tax, a more aggressive Fed, etc.). We answer your frequently asked questions and conclude the Fed will remain the primary inflation fighter in Washington.

MORGAN STANLEY & CO. LLC

Ariana Salvatore

STRATEGIST

Ariana.Salvatore@morganstanley.com

+1 +1-212-761-1779

Michael D Zezas, CFA

STRATEGIST

Michael.Zezas@morganstanley.com

+1 212 761-8609

Sarah A Wolfe

ECONOMIST

Sarah.Wolfe@morganstanley.com

+1 212 761-0857

Morgan Stanley does and seeks to do business with companies covered in Morgan Stanley Research. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of Morgan Stanley Research. Investors should consider Morgan Stanley Research as only a single factor in making their investment decision.

For analyst certification and other important disclosures, refer to the Disclosure Section, located at the end of this report.

When it Comes to Fighting Inflation, Look to the Fed, Not Congress

President Biden continues to signal that blunting inflation is a top priority for his administration. Furthermore, Democrats' electoral prospects appear increasingly tied to the inflation trajectory. Hence, investors are increasingly focused on the likelihood of enacting various policy options that policy-makers have promoted as dealing with inflation. Our focus here is not on the efficacy of those policies if enacted, but rather their prospects for enactment. To that end, we evaluate some of the frequently asked questions that we receive below.

1) What legislative options are there? Little that's viable, in our view

Lawmakers have proposed a variety of solutions to tame rising prices, including a windfall profits tax on oil and gas companies, a gas tax holiday for consumers, or a 'use it or lose it' policy for drilling leases to shore up supply. However, these face an uphill battle in Congress as procedural constraints limit leadership's ability to move them through both chambers. Some details on those proposals are below:

- **Windfall profits tax:** Sen. Sheldon Whitehouse (D-R.I.) and Rep. Ro Khanna (D-CA) put forward a [proposal](#) that would put a 50% per barrel tax on the difference between crude oil prices and the average between 2015 and 2019, with revenues returned to consumers as a rebate. Similarly, Sen. Sanders (I-VT) introduced a [bill](#) that would place a 95% tax on excess profits of corporations with more than \$500 million in yearly revenue.
- **Gas tax holiday:** Since March, lawmakers have been [discussing](#) the potential for a suspension of the federal gas tax until 2023, which is currently ~18c per gallon. However, moderates in the Democratic caucus have been [hesitant](#) to support the policy given that the gas tax flows into the Highway Trust Fund, which is used to support infrastructure projects across the country.
- **'Use it or lose it' for drilling permits:** Speaker Pelosi has expressed support for such a [proposal](#), which could compel oil and gas companies sitting on non-producing acres to either begin producing from their land or pay a fee for each idled well.

However, in our view, these proposals are limited in terms of both procedural hurdles to passage as well as potential impact on the macro environment: As we note above, any proposal in Congress is subject to a number of procedural constraints, most notably the filibuster in the Senate, which requires legislation to garner consent from at least ten Republicans in that chamber (this reality likely blocks the 'use it or lose it' permit proposal). Although the reconciliation process presents an alternative vehicle for tax increases to pass without Republican support, any provision's inclusion would require support from all 50 Senate Democrats. House and Senate moderates have come out in [opposition](#) of a gas tax holiday and several centrists Senate Democrats have been reluctant to publicly support a windfall profits tax. Such opposition may be fueled by research questioning the impact of these policy options. For example, the [Congressional Research Service](#) notes that the last windfall profits tax (which was imposed in 1980

under President Carter) led to an 8% decline in domestic oil production and a 13% increase in imports. Similarly, recent [analysis](#) according to the Penn Wharton Budget Model shows that a suspension of the federal gas tax would have a minimal impact on consumers and reduce federal tax revenue by ~\$20 billion.

Yet, there's real prospects for a Build Back Better-like reconciliation bill that includes some deficit reduction: Media reporting in recent weeks indicate a restart in negotiations between Senator Manchin – a key swing vote in the 50/50 Senate – and Majority Leader Schumer on a more targeted reconciliation package than the original 'Build Back Better' concerning deficit reduction as well as some other priorities. We outlined the potential impacts from that legislation in [Public Policy Brief: The Read on Reconciliation \(10 Jun 2022\)](#), but note that its ability to tame inflation will depend on the structure of the revenue raisers, which are still far from certain.

2) What might the White House do on its own? A 'get caught trying' strategy

Given the constraints described above, we also consider policy options that the executive branch can exercise unilaterally. The impact of some of these options on inflation may be limited or uncertain, but the motivation to exercise them is high as the administration likely wants actions to mirror its message that it is focused on reducing inflation. Some of the policies (some proposed, some already enacted) and their potential impact are described below:

- **Strategic Petroleum Reserve (SPR) release:** In a White House [fact sheet](#) the president outlined his plan to increase oil supply by releasing 1 million barrels of oil per day from the Strategic Petroleum Reserve for the next six months. The president suggested that the release could drive gas prices down from 10c to 35c per gallon. However, our oil strategists have noted that the releases [have not](#) worked to cool the market, as the International Energy Agency [estimates](#) that the releases are only replacing about a third of the supply that is lost per day due to the conflict in Ukraine (3 million barrels per day).
- **Leveraging foreign policy relationships to encourage allies and other players to boost production:** The president also noted in the fact sheet his plan to engage with allies to persuade them to release an additional 60 million barrels of oil from other countries' reserves. The US has also been [working to improve relations with key South American countries](#) to encourage production, and continuing to engage in the JCPOA negotiations to bring Iranian supply back to market. However, thus far efforts with non-allies have met some resistance: the administration received [pushback](#) from lawmakers of both parties amid media reports of potential rollback of sanctions on Venezuela in exchange for higher levels of production, and the negotiations to restore the Joint Comprehensive Plan of Action (the Iran Nuclear Agreement) and bring some Iranian supply back online have faltered. Lawmakers including Senate Foreign Relations Committee Chair Menendez recently [signaled](#) that those talks have come to a close.
- **Utilizing the FTC to go after companies' "price gouging":** The president has [called](#) on the FTC to investigate behavior from energy companies for 'anti-consumer' behavior, on account of the difference between the price of unfinished gasoline and the average price at the pump, which has now surpassed \$5 nationally. The FTC can

conduct investigations into price gouging and anti-consumer behavior, but relies on Congress for expanded resources and authorities. The House recently passed the Consumer Fuel Price Gouging Prevention Act, which expands the FTC's authority to investigate potential instances of price gouging and delivers state authorities enhanced enforcement power through civil court action; however, for the reasons we mention above, passage in the Senate comes with its own set of challenges.

3) What about reducing tariffs on China? We see scope for limited action only, and a hawkish posture should continue

Media reports recently have indicated that the administration is considering relieving some tariffs on certain Chinese imports to blunt the impact of inflation:

This is something the executive branch could accomplish without congressional approval, through the office of the US Trade Representative. However, our economists' view is that the impact from tariff relief on select goods would be minimal in terms of taming inflation. In recent [research](#) they refer back to a [study](#) from the Peterson Institute for International Economics earlier this year stating that the direct effect of tariff removal would "put only a small, short-lived dent in overall inflation" of 0.26pp (for CPI, or 0.5pp on PCE).

Hence, we do not expect broad-based tariff rollback given the trade-off between limited GDP impact and the political risk in an election year of not appearing hawkish with respect to China: A unilateral rollback of tariffs absent concession from China would be, in the USTR's [words](#), equivalent to the sacrifice of leverage in negotiations. For that reason, reports [are indicating](#) that the administration is considering targeting certain items (consumer goods, for example) for relief. In our view, if this limited or temporary tariff removal is announced, it will likely be paired with some incremental hawkish actions. These actions could include: potential new export restrictions on other items, a Section 301 announcement, explicit support for outbound investment restrictions, or others that we detail in [Public Policy Brief: What If? US/China Catalysts \(12 Apr 2022\)](#). Given the limited scope, we expect that this event is neither a panacea for inflation concerns in the US nor a meaningful new incentive for capital to flow to China.

4) Is the Fed, then, the main inflation fighter in DC? Yes

The main tool to fight inflation is through monetary policy: The Fed's two mandates – promote maximum employment and keep prices stable – can be achieved via its primary tool of interest rates. Through raising interest rates, interest rate-sensitive sectors of the economy, namely housing, consumption, and business investment, will pull back demand. Even if supply constraints do not ease, the softening in demand should help to alleviate inflationary pressures.

At the June FOMC meeting, the Fed delivered a 75bp rate hike and reiterated that it is "strongly committed" to reducing inflation: With inflation prints set to remain elevated through the summer, [we expect more aggressive tightening to come](#). We see the Fed delivering another 75bp hike at its July meeting and our modeling suggests that it will take a steady diet of 50bp increases per meeting through November to push GDP growth below potential. A final 25bp hike at the December meeting brings the mid-point of the federal funds target range to 3.625% at end-2022.

By pushing growth below potential, the Fed is creating slack in the economy and labor market, which should in turn ease inflation: Sensitivity in aggregate demand directly exposed to higher interest rates (consumption and housing primarily) pushes GDP growth below its potential to 1.4% 4Q/4Q in 2022 and 1.6% in 2023 (4Q/4Q). Our quarterly path has real GDP growth running between 1.5-1.8% Q/Q annualized growth throughout 2023. Consumption will come down on a stronger [pullback in durable goods expenditures](#) from higher interest rates, as well as moderation in housing services and home-related spending. On housing, higher rates will slow residential construction meaningfully, reducing supply further, while ongoing affordability issues and higher mortgages rates will greatly reduce demand for housing. We see residential investment declining by 5.9% 4Q/4Q in 2022 and 1.1% in 2023. This slower growth should alleviate labor tightness, and we now expect the unemployment rate to tick up 20bp in 2H23 to 3.8%.

As the Fed works to slow economic activity, measures of inflation should follow. We expect headline PCE inflation to come down to 5.3%Y by 4Q22 and 1.9%Y by 4Q23. Core PCE inflation is forecast to moderate to 4.1%Y by 4Q22 and 2.6%Y by 4Q23.

Investors need to be watching the data and thinking like the Fed: What data will it have in hand before each FOMC meeting that would push it to change its policy guidance or not? By the September meeting, the Fed will have CPI inflation for July in August in hand, which should continue to show elevated prints on a Y/Y basis, but M/M there is a notable deceleration. We forecast core CPI to moderate from 0.6%M in May to 0.4%M in June and 0.3%M in July and August, as core goods inflation declines M/M starting in July (data available in August), and core services inflation cools.

A further re-acceleration in inflation that is broad-based (similar to the May print) would push the Fed to act more aggressively in the back half of the year, lifting policy rates well above "neutral" (2.5%) in order to drive down economic activity. However, it is important to note that policy works with a lag, and while we see some immediate effects in the housing market and in financial conditions, we believe that the front-loading of policy in 2022 will most significantly impact activity in 2023.

Disclosure Section

The information and opinions in Morgan Stanley Research were prepared by Morgan Stanley & Co. LLC, and/or Morgan Stanley C.T.V.M. S.A., and/or Morgan Stanley Mexico, Casa de Bolsa, S.A. de C.V., and/or Morgan Stanley Canada Limited. As used in this disclosure section, "Morgan Stanley" includes Morgan Stanley & Co. LLC, Morgan Stanley C.T.V.M. S.A., Morgan Stanley Mexico, Casa de Bolsa, S.A. de C.V., Morgan Stanley Canada Limited and their affiliates as necessary.

For important disclosures, stock price charts and equity rating histories regarding companies that are the subject of this report, please see the Morgan Stanley Research Disclosure Website at www.morganstanley.com/researchdisclosures, or contact your investment representative or Morgan Stanley Research at 1585 Broadway, (Attention: Research Management), New York, NY, 10036 USA.

For valuation methodology and risks associated with any recommendation, rating or price target referenced in this research report, please contact the Client Support Team as follows: US/Canada +1 800 303-2495; Hong Kong +852 2848-5999; Latin America +1 718 754-5444 (U.S.); London +44 (0)20-7425-8169; Singapore +65 6834-6860; Sydney +61 (0)2-9770-1505; Tokyo +81 (0)3-6836-9000. Alternatively you may contact your investment representative or Morgan Stanley Research at 1585 Broadway, (Attention: Research Management), New York, NY 10036 USA.

Analyst Certification

The following analysts hereby certify that their views about the companies and their securities discussed in this report are accurately expressed and that they have not received and will not receive direct or indirect compensation in exchange for expressing specific recommendations or views in this report: Ariana Salvatore; Michael D Zezas, CFA.

Global Research Conflict Management Policy

Morgan Stanley Research has been published in accordance with our conflict management policy, which is available at www.morganstanley.com/institutional/research/conflict/policies. A Portuguese version of the policy can be found at www.morganstanley.com.br

Important Regulatory Disclosures on Subject Companies

The equity research analysts or strategists principally responsible for the preparation of Morgan Stanley Research have received compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors, firm revenues and overall investment banking revenues. Equity Research analysts' or strategists' compensation is not linked to investment banking or capital markets transactions performed by Morgan Stanley or the profitability or revenues of particular trading desks.

Morgan Stanley and its affiliates do business that relates to companies/instruments covered in Morgan Stanley Research, including market making, providing liquidity, fund management, commercial banking, extension of credit, investment services and investment banking. Morgan Stanley sells to and buys from customers the securities/instruments of companies covered in Morgan Stanley Research on a principal basis. Morgan Stanley may have a position in the debt of the Company or instruments discussed in this report. Morgan Stanley trades or may trade as principal in the debt securities (or in related derivatives) that are the subject of the debt research report.

Certain disclosures listed above are also for compliance with applicable regulations in non-US jurisdictions.

STOCK RATINGS

Morgan Stanley uses a relative rating system using terms such as Overweight, Equal-weight, Not-Rated or Underweight (see definitions below). Morgan Stanley does not assign ratings of Buy, Hold or Sell to the stocks we cover. Overweight, Equal-weight, Not-Rated and Underweight are not the equivalent of buy, hold and sell. Investors should carefully read the definitions of all ratings used in Morgan Stanley Research. In addition, since Morgan Stanley Research contains more complete information concerning the analyst's views, investors should carefully read Morgan Stanley Research, in its entirety, and not infer the contents from the rating alone. In any case, ratings (or research) should not be used or relied upon as investment advice. An investor's decision to buy or sell a stock should depend on individual circumstances (such as the investor's existing holdings) and other considerations.

Global Stock Ratings Distribution

(as of May 31, 2022)

The Stock Ratings described below apply to Morgan Stanley's Fundamental Equity Research and do not apply to Debt Research produced by the Firm. For disclosure purposes only (in accordance with FINRA requirements), we include the category headings of Buy, Hold, and Sell alongside our ratings of Overweight, Equal-weight, Not-Rated and Underweight. Morgan Stanley does not assign ratings of Buy, Hold or Sell to the stocks we cover. Overweight, Equal-weight, Not-Rated and Underweight are not the equivalent of buy, hold, and sell but represent recommended relative weightings (see definitions below). To satisfy regulatory requirements, we correspond Overweight, our most positive stock rating, with a buy recommendation; we correspond Equal-weight and Not-Rated to hold and Underweight to sell recommendations, respectively.

STOCK RATING CATEGORY	COVERAGE UNIVERSE		INVESTMENT BANKING CLIENTS (IBC)			OTHER MATERIAL INVESTMENT SERVICES CLIENTS (MISC)	
	COUNT	% OF TOTAL	COUNT	% OF TOTAL IBC	% OF RATING CATEGORY	COUNT	% OF TOTAL OTHER MISC
Overweight/Buy	1398	39%	344	44%	25%	599	39%
Equal-weight/Hold	1576	45%	354	45%	22%	721	47%
Not-Rated/Hold	1	0%	1	0%	100%	0	0%
Underweight/Sell	565	16%	86	11%	15%	211	14%
TOTAL	3,540		785			1531	

Data include common stock and ADRs currently assigned ratings. Investment Banking Clients are companies from whom Morgan Stanley received investment banking compensation in the last 12 months. Due to rounding off of decimals, the percentages provided in the "% of total" column may not add up to exactly 100 percent.

Analyst Stock Ratings

Overweight (O). The stock's total return is expected to exceed the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Equal-weight (E). The stock's total return is expected to be in line with the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Not-Rated (NR). Currently the analyst does not have adequate conviction about the stock's total return relative to the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Underweight (U). The stock's total return is expected to be below the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Unless otherwise specified, the time frame for price targets included in Morgan Stanley Research is 12 to 18 months.

Analyst Industry Views

Attractive (A): The analyst expects the performance of his or her industry coverage universe over the next 12-18 months to be attractive vs. the relevant broad market benchmark, as indicated below.

In-Line (I): The analyst expects the performance of his or her industry coverage universe over the next 12-18 months to be in line with the relevant broad market benchmark, as indicated below.

Cautious (C): The analyst views the performance of his or her industry coverage universe over the next 12-18 months with caution vs. the relevant broad market benchmark, as indicated below.

Benchmarks for each region are as follows: North America - S&P 500; Latin America - relevant MSCI country index or MSCI Latin America Index; Europe - MSCI Europe; Japan - TOPIX; Asia - relevant MSCI country index or MSCI sub-regional index or MSCI AC Asia Pacific ex Japan Index.

Important Disclosures for Morgan Stanley Smith Barney LLC & E*TRADE Securities LLC Customers

Important disclosures regarding the relationship between the companies that are the subject of Morgan Stanley Research and Morgan Stanley Smith Barney LLC or Morgan Stanley or any of their affiliates, are available on the Morgan Stanley Wealth Management disclosure website at www.morganstanley.com/online/researchdisclosures. For Morgan Stanley specific disclosures, you may refer to www.morganstanley.com/researchdisclosures.

Each Morgan Stanley research report is reviewed and approved on behalf of Morgan Stanley Smith Barney LLC and E*TRADE Securities LLC. This review and approval is conducted by the same person who reviews the research report on behalf of Morgan Stanley. This could create a conflict of interest.

Other Important Disclosures

Morgan Stanley Research policy is to update research reports as and when the Research Analyst and Research Management deem appropriate, based on developments with the issuer, the sector, or the market that may have a material impact on the research views or opinions stated therein. In addition, certain Research publications are intended to be updated on a regular periodic basis (weekly/monthly/quarterly/annual) and will ordinarily be updated with that frequency, unless the Research Analyst and Research Management determine that a different publication schedule is appropriate based on current conditions. Morgan Stanley is not acting as a municipal advisor and the opinions or views contained herein are not intended to be, and do not constitute, advice within the meaning of Section 975 of the Dodd-Frank Wall Street Reform and Consumer Protection Act.

Morgan Stanley produces an equity research product called a "Tactical Idea." Views contained in a "Tactical Idea" on a particular stock may be contrary to the recommendations or views expressed in research on the same stock. This may be the result of differing time horizons, methodologies, market events, or other factors. For all research available on a particular stock, please contact your sales representative or go to Matrix at <http://www.morganstanley.com/matrix>. Morgan Stanley Research is provided to our clients through our proprietary research portal on Matrix and also distributed electronically by Morgan Stanley to clients. Certain, but not all, Morgan Stanley Research products are also made available to clients through third-party vendors or redistributed to clients through alternate electronic means as a convenience. For access to all available Morgan Stanley Research, please contact your sales representative or go to Matrix at <http://www.morganstanley.com/matrix>.

Any access and/or use of Morgan Stanley Research is subject to Morgan Stanley's Terms of Use (<http://www.morganstanley.com/terms.html>). By accessing and/or using Morgan Stanley Research, you are indicating that you have read and agree to be bound by our Terms of Use (<http://www.morganstanley.com/terms.html>). In addition you consent to Morgan Stanley processing your personal data and using cookies in accordance with our Privacy Policy and our Global Cookies Policy (http://www.morganstanley.com/privacy_pledge.html), including for the purposes of setting your preferences and to collect readership data so that we can deliver better and more personalized service and products to you. To find out more information about how Morgan Stanley processes personal data, how we use cookies and how to reject cookies see our Privacy Policy and our Global Cookies Policy (http://www.morganstanley.com/privacy_pledge.html).

If you do not agree to our Terms of Use and/or if you do not wish to provide your consent to Morgan Stanley processing your personal data or using cookies please do not access our research.

Morgan Stanley Research does not provide individually tailored investment advice. Morgan Stanley Research has been prepared without regard to the circumstances and objectives of those who receive it. Morgan Stanley recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial adviser. The appropriateness of an investment or strategy will depend on an investor's circumstances and objectives. The securities, instruments, or strategies discussed in Morgan Stanley Research may not be suitable for all investors, and certain investors may not be eligible to purchase or participate in some or all of them. Morgan Stanley Research is not an offer to buy or sell or the solicitation of an offer to buy or sell any security/instrument or to participate in any particular trading strategy. The value of and income from your investments may vary because of changes in interest rates, foreign exchange rates, default rates, prepayment rates, securities/instruments prices, market indexes, operational or financial conditions of companies or other factors. There may be time limitations on the exercise of options or other rights in securities/instruments transactions. Past performance is not necessarily a guide to future performance. Estimates of future performance are based on assumptions that may not be realized. If provided, and unless otherwise stated, the closing price on the cover page is that of the primary exchange for the subject company's securities/instruments.

The fixed income research analysts, strategists or economists principally responsible for the preparation of Morgan Stanley Research have received compensation based upon various factors, including quality, accuracy and value of research, firm profitability or revenues (which include fixed income trading and capital markets profitability or revenues), client feedback and competitive factors. Fixed Income Research analysts', strategists' or economists' compensation is not linked to investment banking or capital markets transactions performed by Morgan Stanley or the profitability or revenues of particular trading desks.

The "Important Regulatory Disclosures on Subject Companies" section in Morgan Stanley Research lists all companies mentioned where Morgan Stanley owns 1% or more of a class of common equity securities of the companies. For all other companies mentioned in Morgan Stanley Research, Morgan Stanley may have an investment of less than 1% in securities/instruments or derivatives of securities/instruments of companies and may trade them in ways different from those discussed in Morgan Stanley Research. Employees of Morgan Stanley not involved in the preparation of Morgan Stanley Research may have investments in securities/instruments or derivatives of securities/instruments of companies mentioned and may trade them in ways different from those discussed in Morgan Stanley Research. Derivatives may be issued by Morgan Stanley or associated persons.

With the exception of information regarding Morgan Stanley, Morgan Stanley Research is based on public information. Morgan Stanley makes every effort to use reliable, comprehensive information, but we make no representation that it is accurate or complete. We have no obligation to tell you when opinions or

information in Morgan Stanley Research change apart from when we intend to discontinue equity research coverage of a subject company. Facts and views presented in Morgan Stanley Research have not been reviewed by, and may not reflect information known to, professionals in other Morgan Stanley business areas, including investment banking personnel.

Morgan Stanley Research personnel may participate in company events such as site visits and are generally prohibited from accepting payment by the company of associated expenses unless pre-approved by authorized members of Research management.

Morgan Stanley may make investment decisions that are inconsistent with the recommendations or views in this report.

To our readers based in Taiwan or trading in Taiwan securities/instruments: Information on securities/instruments that trade in Taiwan is distributed by Morgan Stanley Taiwan Limited ("MSTL"). Such information is for your reference only. The reader should independently evaluate the investment risks and is solely responsible for their investment decisions. Morgan Stanley Research may not be distributed to the public media or quoted or used by the public media without the express written consent of Morgan Stanley. Any non-customer reader within the scope of Article 7-1 of the Taiwan Stock Exchange Recommendation Regulations accessing and/or receiving Morgan Stanley Research is not permitted to provide Morgan Stanley Research to any third party (including but not limited to related parties, affiliated companies and any other third parties) or engage in any activities regarding Morgan Stanley Research which may create or give the appearance of creating a conflict of interest. Information on securities/instruments that do not trade in Taiwan is for informational purposes only and is not to be construed as a recommendation or a solicitation to trade in such securities/instruments. MSTL may not execute transactions for clients in these securities/instruments.

Morgan Stanley is not incorporated under PRC law and the research in relation to this report is conducted outside the PRC. Morgan Stanley Research does not constitute an offer to sell or the solicitation of an offer to buy any securities in the PRC. PRC investors shall have the relevant qualifications to invest in such securities and shall be responsible for obtaining all relevant approvals, licenses, verifications and/or registrations from the relevant governmental authorities themselves. Neither this report nor any part of it is intended as, or shall constitute, provision of any consultancy or advisory service of securities investment as defined under PRC law. Such information is provided for your reference only.

Morgan Stanley Research is disseminated in Brazil by Morgan Stanley C.T.V.M. S.A. located at Av. Brigadeiro Faria Lima, 3600, 6th floor, São Paulo - SP, Brazil; and is regulated by the Comissão de Valores Mobiliários; in Mexico by Morgan Stanley México, Casa de Bolsa, S.A. de C.V. which is regulated by Comisión Nacional Bancaria y de Valores. Paseo de los Tamarindos 90, Torre 1, Col. Bosques de las Lomas Floor 29, 05120 Mexico City; in Japan by Morgan Stanley MUFG Securities Co., Ltd. and, for Commodities related research reports only, Morgan Stanley Capital Group Japan Co., Ltd; in Hong Kong by Morgan Stanley Asia Limited (which accepts responsibility for its contents) and by Morgan Stanley Asia International Limited, Hong Kong Branch; in Singapore by Morgan Stanley Asia (Singapore) Pte. (Registration number 199206298Z) and/or Morgan Stanley Asia (Singapore) Securities Pte Ltd (Registration number 200008434H), regulated by the Monetary Authority of Singapore (which accepts legal responsibility for its contents and should be contacted with respect to any matters arising from, or in connection with, Morgan Stanley Research) and by Morgan Stanley Asia International Limited, Singapore Branch (Registration number T11FC0207F); in Australia to "wholesale clients" within the meaning of the Australian Corporations Act by Morgan Stanley Australia Limited A.B.N. 67 003 734 576, holder of Australian financial services license No. 233742, which accepts responsibility for its contents; in Australia to "wholesale clients" and "retail clients" within the meaning of the Australian Corporations Act by Morgan Stanley Wealth Management Australia Pty Ltd (A.B.N. 19 009 145 555, holder of Australian financial services license No. 240813, which accepts responsibility for its contents; in Korea by Morgan Stanley & Co International plc, Seoul Branch; in India by Morgan Stanley India Company Private Limited; in Canada by Morgan Stanley Canada Limited, which has approved of and takes responsibility for its contents in Canada; in Germany and the European Economic Area where required by Morgan Stanley Europe S.E., authorised and regulated by Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin) under the reference number 149169; in the US by Morgan Stanley & Co. LLC, which accepts responsibility for its contents. Morgan Stanley & Co. International plc, authorized by the Prudential Regulatory Authority and regulated by the Financial Conduct Authority and the Prudential Regulatory Authority, disseminates in the UK research that it has prepared, and approves solely for the purposes of section 21 of the Financial Services and Markets Act 2000, research which has been prepared by any of its affiliates. RMB Morgan Stanley Proprietary Limited is a member of the JSE Limited and A2X (Pty) Ltd. RMB Morgan Stanley Proprietary Limited is a joint venture owned equally by Morgan Stanley International Holdings Inc. and RMB Investment Advisory (Proprietary) Limited, which is wholly owned by FirstRand Limited. The information in Morgan Stanley Research is being disseminated by Morgan Stanley Saudi Arabia, regulated by the Capital Market Authority in the Kingdom of Saudi Arabia, and is directed at Sophisticated investors only.

The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (DIFC Branch), regulated by the Dubai Financial Services Authority (the DFSA), and is directed at Professional Clients only, as defined by the DFSA. The financial products or financial services to which this research relates will only be made available to a customer who we are satisfied meets the regulatory criteria to be a Professional Client. A distribution of the different MS Research ratings or recommendations, in percentage terms for Investments in each sector covered, is available upon request from your sales representative.

The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (QFC Branch), regulated by the Qatar Financial Centre Regulatory Authority (the QFCRA), and is directed at business customers and market counterparties only and is not intended for Retail Customers as defined by the QFCRA.

As required by the Capital Markets Board of Turkey, investment information, comments and recommendations stated here, are not within the scope of investment advisory activity. Investment advisory service is provided exclusively to persons based on their risk and income preferences by the authorized firms. Comments and recommendations stated here are general in nature. These opinions may not fit to your financial status, risk and return preferences. For this reason, to make an investment decision by relying solely to this information stated here may not bring about outcomes that fit your expectations.

The trademarks and service marks contained in Morgan Stanley Research are the property of their respective owners. Third-party data providers make no warranties or representations relating to the accuracy, completeness, or timeliness of the data they provide and shall not have liability for any damages relating to such data. The Global Industry Classification Standard (GICS) was developed by and is the exclusive property of MSCI and S&P.

Morgan Stanley Research, or any portion thereof may not be reprinted, sold or redistributed without the written consent of Morgan Stanley.

Indicators and trackers referenced in Morgan Stanley Research may not be used as, or treated as, a benchmark under Regulation EU 2016/1011, or any other similar framework.

The issuers and/or fixed income products recommended or discussed in certain fixed income research reports may not be continuously followed. Accordingly, investors should regard those fixed income research reports as providing stand-alone analysis and should not expect continuing analysis or additional reports relating to such issuers and/or individual fixed income products.

Morgan Stanley may hold, from time to time, material financial and commercial interests regarding the company subject to the Research report.

The following authors are Fixed Income Research Analysts/Strategists and are not opining on or expressing recommendations on equity securities: Michael D Zezas, CFA; Ariana Salvatore.

The following authors are neither Equity Research Analysts/Strategists nor Fixed Income Research Analysts/Strategists and are not opining on or expressing recommendations on equity or fixed income securities: Sarah A Wolfe.

© 2022 Morgan Stanley